Overview:
Non–muscle-invasive bladder cancer (NMIBC) represents the majority of newly diagnosed bladder cancers, yet remains associated with high rates of recurrence and progression despite standard therapies. Management is increasingly complex due to ongoing BCG shortages, limited durability of conventional intravesical treatments, and the rapid emergence of novel immunotherapies, gene therapies, and advanced drug-delivery platforms. Clinicians continue to face challenges in risk stratification, treatment sequencing, and integrating newly approved and investigational agents into personalized care plans.
This live, CME-certified virtual program will be delivered
using the Medical Crossfire® format, which leverages expert debate and
multidisciplinary discussion to translate emerging clinical data into
practical, real-world decision-making. The virtual format enables broad
participation by urologists, medical oncologists, and advanced practice
providers, facilitating timely education and interactive exchange on evolving
NMIBC treatment strategies without geographic barriers.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Implement best practices for the accurate diagnosis and risk stratification of non–muscle-invasive bladder cancer (NMIBC)
- Describe the mechanisms of action and supporting clinical trial data for recently approved and emerging therapies in NMIBC
- Integrate novel therapies into personalized care plans for patients with NMIBC
- Apply multidisciplinary care strategies to optimize outcomes in patients with NMIBC, including management of treatment-related AEs and effective coordination of care